Publications

Defining the NSD2 interactome: PARP1 PARylation reduces NSD2 histone methyltransferase activity and impedes chromatin binding

Huang X, LeDuc RD, Fornelli L, Schunter AJ, Bennett RL, Kelleher NL, Licht JD.

J Biol chem, 294 (33), pp. 12459-12471, 2019.
10.1074/jbc.RA118.006159
https://www.ncbi.nlm.nih.gov/pubmed/31248990

A Mutation in Histone H2B Represents a New Class of Oncogenic Driver

Bennett RL, Bele A, Small EC, Will CM, Nabet B, Oyer JA, Huang X, Ghosh RP, Grzybowski AT, Yu T, Zhang Q, Riva A, Lele TP, Schatz GC, Kelleher NL, Ruthenburg AJ, Liphardt J, Licht JD.

Cancer Discovery, 9 (10), pp. 1438-1451, 2019.
10.1158/2159-8290
https://cancerdiscovery.aacrjournals.org/content/9/10/1438.long

An activating mutation of the NSD2 histone methyltransferase drives oncogenic reprogramming in acute lymphocytic leukemia.

Swaroop A, Oyer JA, Will CM, Huang X, Yu W, Troche C, Bulic M, Durham BH, Wen QJ, Crispino JD, MacKerell AD Jr, Bennett RL, Kelleher NL, Licht JD.

Oncogene, (), pp. , 2018.
10.1038/s41388-018-0474-y

The Role of Nuclear Receptor–Binding SET Domain Family Histone Lysine Methyltransferases in Cancer

Bennett, RL; Swaroop, A; Troche, C; Licht, JD.

Cold Spring Harbor Perspectives in Medicine, (), pp. , 2017.
10.1101/cshperspect.a026708
http://perspectivesinmedicine.cshlp.org/content/early/2017/02/13/cshperspect.a026708.full.pdf+html

Post transcriptional control of the epigenetic stem cell regulator PLZF by sirtuin and HDAC deacetylases

McConnell, MJ; Durand, L; Langley, E; Coste-Sarguet, L; Zelent, A; Chomienne, C; Kouzarides, T; Licht, JD; Guidez, F.

Epigenetics & Chromatin, 24 (8), pp. 38, 2016.
10.1186/s13072-015-0030-8
Pubmed https://www.ncbi.nlm.nih.gov/pubmed/26405459

Increased protein processing gene signature in HDACi-resistant cells predicts response to proteasome inhibitors

Dupéré-Richer, D; Kinal, M; Pettersson, F; Emond, A; Calvo-Vidal, MN; Nichol, JN; Guilbert, C; Plourde, D; Klein, Oros K; Nielsen, TH; Ezponda, T; Licht, JD; Johnson, NA; Assouline, S; Cerchietti, WH; Miller, Jr, WH; Mann, KK.

Leuk Lymphoma, 58 (1), pp. 218-221, 2016.
10.1080/10428194.2016.1180684
Pubmed https://www.ncbi.nlm.nih.gov/pubmed/27185211

H3K27 Methylation: A Focal Point of Epigenetic Deregulation in Cancer

Nichol, JN; Dupéré-Richer, D; Ezponda, T; Licht, JD; Miller, Jr, WH.

Adv Cancer Res, 131 (0), pp. 59-95, 2016.
10.1016/bs.acr.2016.05.001
Pubmed https://www.ncbi.nlm.nih.gov/pubmed/27451124

EZH2 and BCL6 Cooperate to Assemble CBX8-BCOR Complex to Repress Bivalent Promoters, Mediate Germinal Center Formation and Lymphomagenesis

Béguelin, W; Teater, M; Gearhart, MD; Fernández, MT Calvo; Goldstein, RL; Cárdenas, MG; Hatzi, K; Rosen, M; Shen, H; Corcoran, CM; Hamline, MY; Gascoyne, RD; Levine, RL; Abdel-Wahab, O; Licht, JD; Shaknovich, R; Elemento, O; Bardwell, VJ; Melnick, AM.

Cancer Cell, 30 (2), pp. 197-213, 2016.
10.1016/j.ccell.2016.07.006
Pubmed https://www.ncbi.nlm.nih.gov/pubmed/27505670

Loss of Mll3 Catalytic Function Promotes Aberrant Myelopoiesis

Arcipowski, KM; Bulic, M; Gurbuxani, S; Licht, JD.

PLoS One, 11 (9), pp. e0162515, 2016.
10.1371/journal.pone.0162515
Pubmed https://www.ncbi.nlm.nih.gov/pubmed/27610619

MMSET/WHSC1 enhances DNA damage repair leading to an increase in resistance to chemotherapeutic agents

Shah, MY; Martinez-Garcia, E; Phillip, JM; Chambliss, AB; Popovic, R; Ezponda, T; Small, EC; Will, C; Phillip, MP; Neri, P; Bahlis, NJ; Wirtz, D; Licht, JD.

Oncogene, 35 (45), pp. 5905-5915, 2016.
10.1038/onc.2016.116
Pubmed https://www.ncbi.nlm.nih.gov/pubmed/27109101

Histone H1 and Chromosomal Protein HMGN2 Regulate Prolactin-Induced STAT5 Transcription Factor Recruitment and Function in Breast Cancer Cells

Schauwecker, SM; Kim, JJ; Licht, JD; Clevenger, CV.

J Biol Chem, (0), pp. , 2016.
10.1074/jbc.M116.764233
Pubmed https://www.ncbi.nlm.nih.gov/pubmed/28035005

Strong expression of EZH2 and accumulation of trimethylated H3K27 in diffuse large B-cell lymphoma independent of cell of origin and EZH2 codon 641 mutation

Zhou, Z; Gao, J; Popovic, R; Wolniak, K; Parimi; Winter, JN; Licht, JD; Chen, YH.

Leuk Lymphoma, 56 (10), pp. 2895-2901, 2015.
10.3109/10428194.2015.1006220
Pubmed https://www.ncbi.nlm.nih.gov/pubmed/25651430

GLI2-dependent c-MYC upregulation mediates resistance of pancreatic cancer cells to the BET bromodomain inhibitor JQ1

Kumar, K; Raza, SS; Knab, LM; Chow, CR; Kwok, B; Bentrem, DJ; Popovic, R; Ebine, K; Licht, JD; Munshi, HG.

Sci Rep, 5 (0), pp. 9489, 2015.
10.1038/srep09489
Pubmed https://www.ncbi.nlm.nih.gov/pubmed/25807524

Unabridged Analysis of Human Histone H3 by Differential Top-Down Mass Spectrometry Reveals Hypermethylated Proteoforms from MMSET/NSD2 Overexpression

Zheng, Y; Fornelli, L; Compton, PS, Sharma, S; Canterbury, J; Mullen, C; Zarbroushov, Fellers, RT; Thomas, PM; Licht, JD; Senko, MW; Kelleher, NL.

Mol Cell Proteomics, 15 (3), pp. 776-90, 2015.
10.1074/mcp.M115.053819
Pubmed https://www.ncbi.nlm.nih.gov/pubmed/26272979

Deregulation of the Ras-Erk Signaling Axis Modulates the Enhancer Landscape

Nabet, B; Broin, PÓ; Reyes, JM; Shieh, K; Lin CY; Will, CM; Popovic, R; Ezponda, T; Bradner, JE; Golden, AA; Licht, JD.

Cell Rep, 12 (8), pp. 1300-1313, 2015.
10.1016/j.celrep.2015.06.078
Pubmed https://www.ncbi.nlm.nih.gov/pubmed/26279576

DNA Methylation Inhibitors in Cancer Therapy: The Immunity Dimension

Licht, JD.

Cell, 162 (5), pp. 938-939, 2015.
10.1016/j.cell.2015.08.005
Pubmed https://www.ncbi.nlm.nih.gov/pubmed/26317460

From anecdote to targeted therapy: the curious case of thalidomide in multiple myeloma

Licht, JD; Shortt, J; Johnstone, R.

Cancer Cell, 25 (1), pp. 9-11, 2014.
10.1016/j.ccr.2013.12.019
Pubmed https://www.ncbi.nlm.nih.gov/pubmed/24434206

Single-cell nucleosome mapping reveals the molecular basis of gene expression heterogeneity

Small, EC; Xi, L; Wang, JP; Widom, J; Licht, JD.

Proc Natl Acad Sci USA, 111 (24), pp. E2462-E2471, 2014.
10.1073/pnas.1400517111
Pubmed https://www.ncbi.nlm.nih.gov/pubmed/24889621

Promyelocytic leukemia zinc finger-retinoic acid receptor α (PLZF-RARα), an oncogenic transcriptional repressor of cyclin-dependent kinase inhibitor 1A (p21WAF/CDKN1A) and tumor protein p53 (TP53) genes

Choi, WI; Yoon, JH; Kim, MY; Koh, DI; Licht, JD; Kim, K; Hur Choi, MW.

J Biol Chem, 289 (27), pp. 18641-18656, 2014.
10.1074/jbc.M113.538777
Pubmed https://www.ncbi.nlm.nih.gov/pubmed/24821728

Histone methyltransferase MMSET/NSD2 alters EZH2 binding and reprograms the myeloma epigenome through global and focal changes in H3K36 and H3K27 methylation

Popovic, R; Martinez-Garcia, E; Giannopoulou, EG; Zhang, Q; Ezponda, T; Shah, MY; Zheng, Y; Will, CM; Small, EC; Hua, Y; Bulic, M; Jiang, Y; Carrara, M; Calogero, RA; Kath, WL; Keller, NL; Wang, JP; Elemento, O; Licht, JD.

PLoS Genet, 10 (9), pp. e1004566, 2014.
10.1371/journal.pgen.1004566
Pubmed https://www.ncbi.nlm.nih.gov/pubmed/25188243

Molecular pathways: deregulation of histone h3 lysine 27 methylation in cancer-different paths, same destination

Ezponda, T; Licht, JD.

Clin Cancer Res, 20 (19), pp. 5001-5008, 2014.
10.1158/1078-0432.CCR-13-2499
Pubmed https://www.ncbi.nlm.nih.gov/pubmed/24987060

DNA hydroxymethylation profiling reveals that WT1 mutations result in loss of TET2 function in acute myeloid leukemia

Rampal, R; Alkalin, A; Madzo, J; Vasanthakumar, A; Pronier, E; Patel, J; Li, Y; Ahn, J; Abdel-Wahab, O; Shih, A; Lu, C; Ward, PS; Tsai, JJ; Hricik, T; Tosello, V; Tallman, JE; Zhao, X; Daniels, D; Dai, Ciminio, L; Aifantis, I; He, C; Fuks, F; Tallman, MS; Ferrando, A; Nimer, S; Paietta, E; Thompson, CB; Licht, JD; Mason, CE; Godley, LA; Melnick, A; Figueroa, ME; Levine, RL.

Cell Rep, 9 (5), pp. 1841-55, 2014.
10.1016/j.celrep.2014.11.004
https://www.ncbi.nlm.nih.gov/pubmed/25482556